Phase 3, single-arm open-label trial to assess the efficacy, safety,pharmacokinetics, and pharmacodynamics of dasiglucagon when administered as a rescue therapy for severe hypoglycemia in pediatric patients aged from 1 to less than 6 years of age with Type 1 Diabetes (T1D)
L
Linda DiMeglio, MD
Primary Investigator
Enrolling By Invitation
1-5 years
All
Phase
N/A
8 participants needed
5 Locations
Brief description of study
The purpose of this trial is to investigate if a single dose of 0.6 mg dasiglucagon is safe, well-tolerated by children and to measure the concentration of dasiglucagon in participants' blood when dasiglucagon is used as a rescue treatment for severe hypoglycemia.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: diabetes,T1D,type I diabetes, Riley
-
Age: Between 1 Years - 5 Years
-
Gender: All
Updated on
13 Sep 2024.
Study ID: PENDO-ZEALAND-2-0, 15496, TX11562
Please visit our main page to search for other studies you may be interested in.
If you need help finding a study or have any questions, please contact us at inhealth@iu.edu
